Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week randomized double-blind placebo-controlled aripiprazole IM depot maintenance study in schizophrenia
2008-002675-27Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aripiprazole in schizophrenia (3 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Time to exacerbation of psychotic symptoms/impending relapse. Started May 2009; status: completed.
02
Drugs
aripiprazole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2008-002675-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002675-27.